Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by <i>KRAS</i> G12C Mutation: A Report of Two Cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38096473.
- Also identified by DOI 10.1200/PO.23.00451 and PMC identifier 10735074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.
Medical subject headings
- Proto-Oncogene Proteins p21(ras)